Doxophylline

Doxophylline is used to treat in following indications: 

• Bronchial asthma,
• Bronchospasm,
• Chronic obstructive pulmonary disease (COPD),
• Pulmonary disease with spastic bronchial component.

1904 generics available

Nikethamide

Nikethamide is indicated in-

• Acute respiratory failure
• Respiratory depression following anesthesia
• CNS depression

1904 generics available

Nilotinib

Treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The study is ongoing and further data will be required to determine long-term outcome.

Treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib. Clinical benefit, such as improvement in disease-related symptoms or increased survival, has not been demonstrated.

1904 generics available

Nimodipine

For the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post ictus neurological condition.

1904 generics available

Nintedanib

Nintedanib is indicated in-

• adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
• adults for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
• adults for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
• combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology after first-line chemotherapy.

1904 generics available

Niraparib

Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

1904 generics available

Nirmatrelvir + Ritonavir

Indicated for mild-to-moderate COVID-19 positive adult and pediatric patients (12 years of age and older weighing at least 40 kg), who are at high risk for progression to severe COVID-19, including hospitalization or death.

1904 generics available

Nitazoxanide

Nitazoxanide is indicated for the treatment of diarrhea caused by Cryptosporidium parvum, Giardia lamblia and Entamoeba histolytica.

1904 generics available

Nitrazepam

Nitrazepam is indicated in disturbances of sleep of various aetiology, insomnia of the neurotics, involutional restlessness, disturbances of sleep of cerebrosclerotic patients, Myoclonic seizures etc.

1904 generics available

Nitrofurantoin

Nitrofurantoin is specifically indicated for the treatment & prophylaxis of urinary tract infections caused by susceptible strains of Escherichia coli, Enterococci, Staphylococcus aureus, Staphylococcus saprophyticus and certain susceptible strains of Klebsiella and Enterobacter species.

1904 generics available

Nitrofurantoin + Nitrofurantoin Microcrystals

For the treatment of and prophylaxis against acute or recurrent, uncomplicated lower urinary tract infections or pyelitis either spontaneous or following surgical procedures. Nitrofurantoin is specifically indicated for the treatment of infections when due to susceptible strains of Escherichia coli, enterococci, staphylococci, Citrobacter, Klebsiella and Enterobacter.

1904 generics available

Nitroglycerin (IV Infusion)

Nitroglycerin Injection is indicated for the treatment of peri-operative hypertension; for controlling of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and beta blockers and for induction of Intraoperative hypotension.

1904 generics available

Doxorubicin Hydrochloride

Doxorubicin Hydrochloride is indicated:

• As a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.
• For the treatment of acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma.

1904 generics available

Nitroglycerin (Ointment)

The ointment will help to relieve the symptom of pain caused by chronic anal fissures.

1904 generics available

Nitroglycerin (Sublingual Spray)

Nitroglycerin sublingual spray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

1904 generics available

Nitroglycerin (Sublingual Tablet)

Nitroglycerin sublingual tablet is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

1904 generics available

Nitroglycerin (Tablet)

Nitroglycerin is indicated for the prophylaxis of angina pectoris. The onset of action is not sufficiently rapid for this form to be useful in aborting an acute anginal episode.

1904 generics available

Doxorubicin Hydrochloride Liposome

Doxorubicin Hydrochloride Liposome injection is indicated for the treatment of:

Ovarian Cancer: Doxorubicin Hydrochloride Liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.

AIDS-Related Kaposi’s Sarcoma: It is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy.

Multiple Myeloma: For the treatment of patients with multiple myeloma in combination with Bortezomib, who have not previously received Bortezomib and have received at least one prior therapy.

Also indicated for the monotherapy for patients with metastatic breast cancer, where patient is associated with increased cardiac risk with conventional Doxorubicin.

1904 generics available

Doxycycline Hydrochloride

Doxycycline Hydrochloride is indicated in the following infections caused by susceptible microorganisms:

• Respiratory tract infections: Pneumonia, influenza, sinusitis, bronchitis, tonsillitis, tracheitis.
• Gastrointestinal tract infections: Cholera, traveler's diarrhea, shigella dysentery, acute intestinal amebiasis.
• ... Read more

1904 generics available

Nivolumab

Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of:

Melanoma:

• patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab.
• patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting.

Non-Small Cell Lung Cancer (NSCLC):

• adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab.
• adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum doublet chemotherapy.
• patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Nivolumab.

Malignant Pleural Mesothelioma: adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab.

Renal Cell Carcinoma (RCC):

• patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab.
• patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib.
• patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.

Classical Hodgkin Lymphoma (cHL): adult patients with classical Hodgkin lymphoma that has relapsed or progressed after

• autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or
• 3 or more lines of systemic therapy that includes autologous HSCT.

Squamous Cell Carcinoma of the Head and Neck (SCCHN): patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy.

Urothelial Carcinoma: patients with locally advanced or metastatic urothelial carcinoma who a: have disease progression during or following platinum-containing chemotherapy; have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Colorectal Cancer: adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as a single agent or in combination with ipilimumab.

Hepatocellular Carcinoma (HCC): patients with hepatocellular carcinoma who have been previously treated with sorafenib, as a single agent or in combination with ipilimumab. a (1.10)

Esophageal Squamous Cell Carcinoma (ESCC): patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.

Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma:

• patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy.
• This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
• Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analog plus dexamethasone is not recommended outside of controlled clinical trials.

1904 generics available